Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab, Trastuzumab, and Sequential Capecitabine in HER2+ Breast Cancer
NCT00964704Phase 2Withdrawn
- Sponsor
- Roche
- Start
- Mar 2011
- Primary completion
- Aug 2013
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of bevacizumab in breast cancer, sponsored by Roche. Planned start Mar 2011; status: withdrawn.
02
Drugs
bevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00964704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00964704.